DJIA 16,399.67 19.26 0.12%
NASDAQ 4,316.07 57.64 1.35%
S&P 500 1,904.01 17.25 0.91%
market minute promo

Eli Lilly & Co. (NYSE: LLY)

63.10 0.52 (0.83%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

LLY $63.10 0.83%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $62.63
Previous Close $62.58
Daily Range $62.40 - $63.10
52-Week Range $48.88 - $67.14
Market Cap $70.5B
P/E Ratio 19.87
Dividend (Yield) $1.96 (3.1%)
Ex-Dividend Date
Dividend Pay Date
08/13/14
09/10/14
Volume 2,829,309
Average Daily Volume 4,203,744
Current FY EPS $2.77

Sector

Healthcare

Industry

Drugs

Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/

News & Commentary

Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?

The world's largest pharmaceutical company, Pfizer, looks lost amid its staggering patent cliff problem. Could this experimental breast cancer drug put Pfizer back on track for growth?

Lilly Announces Plan to Realign Puerto Rico Manufacturing Operations

XLV, MDT, LLY, AGN: Large Outflows Detected at ETF

Can Dividend Stock GlaxoSmithKline plc Bounce Back?

British pharma GlaxoSmithKline is being accused of corruption in yet another country, the United Arab Emirates. Given all the problems facing the company these days, can Glaxo turn things around?

Insider Trading Alert - LLY, ROSE And SCCO Traded By Insiders

Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues - Analyst Blog

Notable ETF Inflow Detected - IVE, WMT, LLY, MET

Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine And Cisplatin

The Most Important Number You Need to Know Before Buying Pfizer Inc. Stock

Every drugmaker faces a dangerous patent cliff, but Pfizer's (PFE) future growth is at stake if it can't develop new blockbusters to bridge the gap.

Why Is Sanofi Betting on MannKind Corporation's Afrezza?

Sanofi's global dominance over the lucrative diabetes market is facing a serious challenge with the patent expiration of Lantus, the most commonly prescribed insulin in the world. Can MannKind's inhaled insulin product help Sanofi retain its edge?

See More LLY News...

LLY's Top Competitors

LLY $63.10 (0.83%)
Current stock: LLY
JNJ $99.20 (0.51%)
Current stock: JNJ
NVS $87.90 (1.47%)
Current stock: NVS
RHHBY $35.85 (1.26%)
Current stock: RHHBY